CompletedPhase 4

MYREPTIC-N® or MY-REPT® in Stable Patients After Kidney Transplant Recipients

South Korea158 participantsStarted 2023-11-14

Plain-language summary

The purpose of this study is to Evaluate the Efficacy and Safety of MYREPTIC-N® or MY-REPT® in Stable Patients after Kidney Transplant Recipients

Age range19 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

✓. Over 19 years old
✓. Patients who at least 1 year after kidney transplant
✓. serum creatinine ≤2.3 mg/dL
✓. Patients on immunosuppressive maintenance therapy using combination of Calcineurin Inhibitor and Mycophenolate Mofetil after kidney transplantation

Incidence of composite efficacy failure

Timeframe: Until 24 weeks

NCT IDNCT06044493

SponsorChong Kun Dang Pharmaceutical

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2025-10-29